Dividend-adjusted total return · Dec 31, 2025 – Nov 4, 2026CANC
| Returns | 1D | 1M | 3M | YTD | 1Y | 3Y | 5Y | MAX |
|---|---|---|---|---|---|---|---|---|
| Total return | +1.9% | +6.0% | +2.3% | +23.5% | +40.0% | +106.6% | — | +81.3% |
| S&P 500 · VOO | +1.6% | −1.6% | 0.0% | +13.4% | +13.5% | +91.7% | +81.2% | — |
Key Statistics
Open all fund facts →- AUM
- $213M
- Expense ratio
- 0.99%
- Distribution yield
- 0.0%
- NAV
- $41.61
- Volume
- 12K
- Avg. volume 30D
- 23K
- High today
- $42.92
- Low today
- $41.86
- Previous close
- $42.10
- 52-week high
- $47.00
- 52-week low
- $30.14
- Our risk indicator
- 4/5
CANC in One Breath
CANC Among Its Peers
YTDEnd-of-day Nov 5, 2026 · 1 ETFs by YTD
$10,000 in CANC
5Y$10,000 in CANC became
$18,128
In the S&P 500 (VOO)
$18,340
Total return, dividends in · Aug 17, 2023 – Nov 4, 2026 · S&P 500 uses VOO
CANC’s Top Holdings
TodayGMABGenmab A/s5.8%LLY5.3%RVMD5.3%MRK4.8%COGT4.6%NOVN.SW4.1%ABBV3.9%EXEL3.8%HALO3.8%ONC3.6%RHHBY3.1%BBIO2.9%BMY2.6%IMNM2.5%JNJ2.5%ELVN2.5%CGON2.4%AZN.L2.3%IDYA2.2%RLAY2.1%LEGN2.1%AMGN35 more
GMAB5.8%LLY5.3%RVMD5.3%MRK4.8%COGT4.6%NOVN.SW4.1%ABBV3.9%EXEL3.8%HALO3.8%ONC3.6%RHHBY3.1%BBIO2.9%45 more
BiotechnologyDrug Manufacturers - General
Tema CANC · 57 holdings · tile size = share of the fund · as of Nov 4, 2026
What CANC Holds
TodayBiotechnology65.0%
GMAB 5.8 · RVMD 5.3 · COGT 4.6 · EXEL 3.8 · HALO 3.8 · ONC 3.6 · BBIO 2.9
Drug Manufacturers - General31.6%
LLY 5.3 · MRK 4.8 · NOVN.SW 4.1 · ABBV 3.9 · RHHBY 3.1 · BMY 2.6 · JNJ 2.5
Medical - Diagnostics & Research1.1%
GH · NTRA
Other holdings2.3%
ANL · CADL · OLMA · CTMX · AVBP · AUTL
Tema CANC · share of the fund by industry · as of Nov 4, 2026
Genmab’s Share of CANC
Today5.8%
$58 of every $1,000 in CANC is Genmab
Genmab held by CANC
$12.4M
Tema CANC · each square = $10 of $1,000 · as of Nov 4, 2026
CANC’s Size vs Its Peers
Today$213Mthe largest ETF
AUM · CANC and the 0 largest peers · Nov 5, 2026
CANC Fee per $100 vs Peers
TodayExpense ratio · peers · Nov 5, 2026
Inside CANC
57 holdings · as of Nov 4, 2026CANC
Tema Oncology ETF
Today| # | Ticker | Company | Weight ▼ |
|---|---|---|---|
| 1 | GMAB | Genmab A/S | 5.85% |
| 2 | LLY | ELI Lilly & | 5.34% |
| 3 | RVMD | Revolution Medicines | 5.33% |
| 4 | MRK | Merck & | 4.79% |
| 5 | COGT | Cogent Biosciences | 4.55% |
| 6 | NOVN.SW | Novartis AG | 4.09% |
| 7 | ABBV | Abbvie | 3.90% |
| 8 | EXEL | Exelixis | 3.81% |
| 9 | HALO | Halozyme Therapeutics | 3.77% |
| 10 | ONC | Beone Medicines | 3.60% |
BiotechnologyDrug Manufacturers - GeneralMedical - DiagnosticsOther
Tema CANC · current holdings by weight · as of Nov 4, 2026 · each tile is one holding · top 20 = 70.2%
How It Compares
CANC
Tema Oncology ETF’s Peers
YTDCANC has no close peers in our data yet: […]
Similar peers · YTD and past-year returns · as of Nov 5, 2026 · sorted by AUM
Head to Head
CANC vs VOO
YTDCANC · Tema Oncology
+23.5%
VOO · S&P 500
+13.4%
Gap
10.2 pts
Tema CANC and Vanguard VOO · YTD total return · as of Nov 5, 2026
CANC vs Its Peer Average
YTDCANCAvsBPeer average
1D+1.9%[…]
1M+6.0%[…]
3M+2.3%[…]
YTD+23.5%[…]
1Y+40.0%[…]
3Y+106.6%[…]
0–0level
0 peers · each row scaled to its leader
The Details
CANC
Risk
1Y4/5our risk indicator
CalmerBumpier
Volatility · 1Y23.49%
Deepest drop · 1Y−13.2%
Lowest point · 5Y−12.3%
52-week range
$42.89
$30.14−8.7% from the high$47.00
Tema CANC · past-year price moves · as of Nov 5, 2026
CANC
Fund Facts
Today2023launched Aug 14
Tracks[…]
Exchange · CUSIPNASDAQ · 87975E701
StructureETF
Leverage1x
Cost on $10,000$99 a year
Go deeper
Tema CANC · fund facts · as of Nov 5, 2026
CANC
Payouts by Year
3Y$0.0196per share, Dec 2025
Distribution yield0.0%
PaidOnce a year, in December
Latest ex-date · paidDec 10 · Dec 11, 2025
3 payouts added up$0.90 a share
Tema CANC · distributions by ex-date · 2023–2025
All Fund FactsDocuments · trading · fees · every payout
Prospectus & Documents
SEC reported portfolio · 2026-08-31 ↗SEC reported portfolio · 2026-05-31 ↗summary prospectus · SEC 497K ↗SEC reported portfolio · 2026-02-28 ↗summary prospectus · SEC 497K ↗SEC reported portfolio · 2025-11-30 ↗SEC reported portfolio · 2025-08-31 ↗SEC reported portfolio · 2025-05-31 ↗summary prospectus · SEC 497K ↗SEC reported portfolio · 2025-02-28 ↗SEC reported portfolio · 2024-11-30 ↗summary prospectus · SEC 497K ↗SEC reported portfolio · 2024-08-31 ↗SEC reported portfolio · 2024-05-31 ↗summary prospectus · SEC 497K ↗SEC reported portfolio · 2024-02-29 ↗SEC reported portfolio · 2023-11-30 ↗SEC reported portfolio · 2023-08-31 ↗summary prospectus · SEC 497K ↗
Trading & Liquidity
Net asset value$41.61
Premium / discount[…]
Median spread · 30D[…]
Volume today12K
Average volume · 30D23K
Shares outstanding[…]
Options[…]
Fees & Costs
Net expense ratio0.99%
Gross expense ratio[…]
Management fee[…]
Cost on $10,000 a year$99.00
Our risk indicator4/5
Estimated yearly cost excludes trading costs and assumes constant assets.
Distributions
| Ex-date | Paid | Per share |
|---|---|---|
| Dec 10, 2025 | Dec 11, 2025 | $0.0196 |
| Dec 11, 2024 | Dec 12, 2024 | $0.73 |
| Dec 13, 2023 | Dec 15, 2023 | $0.15 |
Issuer contentFrom TemaHear the strategy from the people behind CANC.No issuer videos have been published for this fund.Are you the issuer? Claim this fund →